英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

bowlder    
n. 圆石头;玉石

圆石头;玉石

bowlder
n 1: a large smooth mass of rock detached from its place of
origin [synonym: {boulder}, {bowlder}]


请选择你想看的字典辞典:
单词字典翻译
Bowlder查看 Bowlder 在百度字典中的解释百度英翻中〔查看〕
Bowlder查看 Bowlder 在Google字典中的解释Google英翻中〔查看〕
Bowlder查看 Bowlder 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Home | BlossomHill Therapeutics
    BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M D , and John Schmid May 20, 2026
  • About | BlossomHill Therapeutics
    About At BlossomHill, we are on a mission to redefine precision medicine and make a leap forward in life expectancy and quality of life for patients
  • Pipeline | BlossomHill Therapeutics
    Our oncology programs aim to outmaneuver treatment resistance and significantly improve the patient’s quality of life by designing small molecules with improved selectivity, durability and safety
  • News | BlossomHill Therapeutics
    BlossomHill Therapeutics Unveils New Pan-KRAS Inhibitor Programs and Announces Upcoming Presentations at AACR Annual Meeting 2026 March 17, 2026
  • Contact | BlossomHill Therapeutics
    Interested in learning more about our pipeline or joining our team? Get in touch with us through via the contact form below
  • Careers | BlossomHill Therapeutics
    Led by successful precision oncology entrepreneurs, we are like-minded scientists and industry leaders working to reach new horizons in cancer drug development and achieve extraordinary outcomes for patients
  • BH-30643 | BlossomHill Therapeutics
    Therefore, BlossomHill Therapeutics’ efforts are ongoing to develop a novel inhibitor that improves clinical outcomes, duration of response and tolerability in patients with locally advanced or metastatic NSCLC harboring EGFR classical and atypical mutations, as well as EGFR resistance mutations following prior EGFR therapy or in patients
  • J. Jean Cui, Ph. D. | BlossomHill Therapeutics
    J Jean Cui, Ph D , the scientific founder, President and CEO of BlossomHill Therapeutics Dr Cui was the scientific founder and Chief Scientific Officer of the San Diego-based oncology biotech company Turning Point Therapeutics, Inc (Turning Point) Turning Point went public on NASDAQ in April 2019 (Ticker: TPTX) and was acquired in August 2022 by Bristol Myers Squibb for $4 1 billion From
  • Clinical Trials | BlossomHill Therapeutics
    Our mission at BlossomHill is to provide people living with cancer the opportunity to experience longer, healthier and more active lives Our goal is to ensure the safety and efficacy of our investigational drugs and advance them through clinical trials and regulatory review to make our therapies widely available for patients who need them
  • BH-30236 | BlossomHill Therapeutics
    At BlossomHill Therapeutics, we are actively developing an orally available, multi-targeted CLK inhibitor (BH-30236) designed to induce splicing alterations in cancerous tissue, promoting the expression of splicing isoforms that favor apoptosis, anti-proliferation, and anti-survival pathways, thereby disrupting the cancer’s ability to





中文字典-英文字典  2005-2009